PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, […]
Tag: Cadrenal Therapeutics
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
PONTE VEDRA, Fla., Aug. 7, 2024 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart […]